Except SRX was self funding through to commercialisation with still now only 56m shares on issue. Whereas OSL, no approvals, no sales and another $10m raised and now over 400m shares on the register.
It is still a speccy and there are question marks about the effectiveness and marketability of their product. But it you are a true believer or speculator then I would say getting a cap raising out of the way at what is a reasonable price gives a solid foundation to go from.
Having been a close follower of SRX for around 15 years I reckon it would be unlikely this will be the final cap raise for OSL even if they get product to market. SRX during their early expansion and revenue growth years dropped 2 or 3 consecutive quarters of serious negative cash flow whilst they built and invested in the business (production capacity, back taxes, sales force and marketing), and from memory cash balance dropped to around $6m before taking off and not looking back.
Sarge
- Forums
- ASX - By Stock
- OSL
- Ann: $10 Million Institutional Placement
OSL
oncosil medical ltd
Add to My Watchlist
5.69%
!
$1.16

Ann: $10 Million Institutional Placement, page-16
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.16 |
Change
-0.070(5.69%) |
Mkt cap ! $16.49M |
Open | High | Low | Value | Volume |
$1.25 | $1.25 | $1.11 | $72.36K | 60.96K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 412 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9286 | 1.160 |
1 | 7500 | 1.080 |
2 | 19761 | 1.050 |
1 | 2500 | 1.030 |
1 | 550 | 1.020 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 412 | 1 |
1.200 | 8677 | 1 |
1.245 | 2418 | 1 |
1.250 | 46027 | 1 |
1.300 | 1500 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online